Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01650805




Registration number
NCT01650805
Ethics application status
Date submitted
18/07/2012
Date registered
26/07/2012
Date last updated
17/11/2014

Titles & IDs
Public title
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Scientific title
A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Secondary ID [1] 0 0
AP24534-12-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Myeloid Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - ponatinib
Treatment: Drugs - imatinib (Gleevec/ Glivec)

Experimental: ponatinib -

Active comparator: imatinib -


Treatment: Drugs: ponatinib
45 mg tablet, taken orally once daily

Treatment: Drugs: imatinib (Gleevec/ Glivec)
400 mg tablet, taken orally once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Major Molecular Response (MMR) Rate at 12 Months
Timepoint [1] 0 0
12 months after first dose
Secondary outcome [1] 0 0
MMR Rate
Timepoint [1] 0 0
5 years after first dose
Secondary outcome [2] 0 0
<10% BCR-ABL^IS Rate
Timepoint [2] 0 0
3 months after first dose
Secondary outcome [3] 0 0
Complete Cytogenetic Response (CCyR) Rate
Timepoint [3] 0 0
12 months after first dose
Secondary outcome [4] 0 0
Progression-free Survival
Timepoint [4] 0 0
Up to 8 years after the last patient's first dose
Secondary outcome [5] 0 0
Overall Survival
Timepoint [5] 0 0
Up to 8 years after the last patient's first dose

Eligibility
Key inclusion criteria
1. CP CML within 6 months of diagnosis

* CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) =100 × 10^9/L platelets (=100,000/mm^3); (v) No evidence of extramedullary disease except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML
2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22) Philadelphia chromosome

* (a)Variant translocations are only allowed provided they are assessable for cytogenetic response utilizing conventional cytogenetic techniques; (b) Conventional chromosome banding must be performed; AND (c) A minimum of 20 metaphases must be assessable at entry
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
4. Adequate hepatic function as defined by the following criteria:

(a) Total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome; (b) Alanine aminotransferase (ALT) =2.5 × ULN; AND (c) Aspartate aminotransferase (AST) =2.5 × ULN
5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN
6. Adequate pancreatic function as defined by serum lipase and amylase =1.5 × ULN
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Received prior imatinib therapy
2. Received prior dasatinib therapy
3. Received prior nilotinib therapy
4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or radiation therapy with the exception of anagrelide or hydroxyurea
5. Major surgery within 28 days prior to initiating therapy
6. History of bleeding disorder unrelated to CML
7. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis
8. History of alcohol abuse
9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)
10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

1. Myocardial infarction, within 6 months prior to randomization
2. Unstable angina within 6 months prior to randomization
3. Congestive heart failure within 6 months prior to randomization
4. History of clinically significant (as determined by the treating physician) atrial arrhythmia or any ventricular arrhythmia
5. Any history of ventricular arrhythmia
6. Cerebrovascular accident or transient ischemic attack within 6 months prior to randomization
7. Any history of peripheral arterial occlusive disease requiring revascularization
8. Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control
12. Taking medications that are known to be associated with Torsades de Pointes
13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection
14. Known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history
15. Pregnant or breastfeeding
16. Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs
17. Diagnosed with or received anticancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)
18. Any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the drug

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2013
Sample size
Target
Accrual to date
Final
307
Recruitment in Australia
Recruitment state(s)
ACT,NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Canberra Hospital, Site #971 - Garran
Recruitment hospital [2] 0 0
Royal North Shore Hospital, Site #941 - Sydney
Recruitment hospital [3] 0 0
Royal Adelaide Hospital, Site #951 - Adelaide
Recruitment hospital [4] 0 0
The Peter MacCallum Cancer Center, Site #950 - East Melbourne
Recruitment hospital [5] 0 0
Box Hill Hospital, Site #940 - Melbourne
Recruitment hospital [6] 0 0
Royal Perth Hospital, Site #972 - Perth
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2065 - Sydney
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
3128 - Melbourne
Recruitment postcode(s) [6] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Delaware
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Utah
Country [31] 0 0
United States of America
State/province [31] 0 0
Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
United States of America
State/province [33] 0 0
West Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Austria
State/province [35] 0 0
Wien
Country [36] 0 0
Belgium
State/province [36] 0 0
Brussel
Country [37] 0 0
Belgium
State/province [37] 0 0
Bruxelles
Country [38] 0 0
Belgium
State/province [38] 0 0
Gent
Country [39] 0 0
Belgium
State/province [39] 0 0
Leuven
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Brno
Country [43] 0 0
Czech Republic
State/province [43] 0 0
Hradec Kralove
Country [44] 0 0
Czech Republic
State/province [44] 0 0
Olomouc
Country [45] 0 0
Czech Republic
State/province [45] 0 0
Praha
Country [46] 0 0
Finland
State/province [46] 0 0
Helsinki
Country [47] 0 0
France
State/province [47] 0 0
Bordeaux
Country [48] 0 0
France
State/province [48] 0 0
Brest
Country [49] 0 0
France
State/province [49] 0 0
Creteil Cedex
Country [50] 0 0
France
State/province [50] 0 0
Le Chesnay Cedex
Country [51] 0 0
France
State/province [51] 0 0
Lille Cedex
Country [52] 0 0
France
State/province [52] 0 0
Marseille
Country [53] 0 0
France
State/province [53] 0 0
Nancy Cedex
Country [54] 0 0
France
State/province [54] 0 0
Nantes Cedex
Country [55] 0 0
France
State/province [55] 0 0
Nice Cedex
Country [56] 0 0
France
State/province [56] 0 0
Paris
Country [57] 0 0
France
State/province [57] 0 0
Pierre Benite
Country [58] 0 0
France
State/province [58] 0 0
Poitiers
Country [59] 0 0
France
State/province [59] 0 0
Toulouse Cedex
Country [60] 0 0
Germany
State/province [60] 0 0
Aachen
Country [61] 0 0
Germany
State/province [61] 0 0
Berlin
Country [62] 0 0
Germany
State/province [62] 0 0
Dresden
Country [63] 0 0
Germany
State/province [63] 0 0
Freiburg
Country [64] 0 0
Germany
State/province [64] 0 0
Hamburg
Country [65] 0 0
Germany
State/province [65] 0 0
Jena
Country [66] 0 0
Germany
State/province [66] 0 0
Koln
Country [67] 0 0
Germany
State/province [67] 0 0
Mannheim
Country [68] 0 0
Germany
State/province [68] 0 0
Munchen
Country [69] 0 0
Hong Kong
State/province [69] 0 0
Hong Kong
Country [70] 0 0
Italy
State/province [70] 0 0
Bari
Country [71] 0 0
Italy
State/province [71] 0 0
Bologna
Country [72] 0 0
Italy
State/province [72] 0 0
Catania
Country [73] 0 0
Italy
State/province [73] 0 0
Genova
Country [74] 0 0
Italy
State/province [74] 0 0
Milan
Country [75] 0 0
Italy
State/province [75] 0 0
Modena
Country [76] 0 0
Italy
State/province [76] 0 0
Monza
Country [77] 0 0
Italy
State/province [77] 0 0
Napoli
Country [78] 0 0
Italy
State/province [78] 0 0
Orbassano
Country [79] 0 0
Italy
State/province [79] 0 0
Rome
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Seoul
Country [81] 0 0
Netherlands
State/province [81] 0 0
Amsterdam
Country [82] 0 0
New Zealand
State/province [82] 0 0
Auckland
Country [83] 0 0
New Zealand
State/province [83] 0 0
Christchurch
Country [84] 0 0
New Zealand
State/province [84] 0 0
Hamilton
Country [85] 0 0
New Zealand
State/province [85] 0 0
Takapuna
Country [86] 0 0
Poland
State/province [86] 0 0
Gdansk
Country [87] 0 0
Poland
State/province [87] 0 0
Krakow
Country [88] 0 0
Poland
State/province [88] 0 0
Lodz
Country [89] 0 0
Poland
State/province [89] 0 0
Rzeszow
Country [90] 0 0
Poland
State/province [90] 0 0
Wroclaw
Country [91] 0 0
Portugal
State/province [91] 0 0
Lisboa
Country [92] 0 0
Puerto Rico
State/province [92] 0 0
San Juan
Country [93] 0 0
Singapore
State/province [93] 0 0
Singapore
Country [94] 0 0
Slovakia
State/province [94] 0 0
Bratislava
Country [95] 0 0
Slovakia
State/province [95] 0 0
Martin
Country [96] 0 0
Spain
State/province [96] 0 0
A Coruna
Country [97] 0 0
Spain
State/province [97] 0 0
Badalona
Country [98] 0 0
Spain
State/province [98] 0 0
Barcelona
Country [99] 0 0
Spain
State/province [99] 0 0
Girona
Country [100] 0 0
Spain
State/province [100] 0 0
Islas Baleares
Country [101] 0 0
Spain
State/province [101] 0 0
Madrid
Country [102] 0 0
Spain
State/province [102] 0 0
Oviedo
Country [103] 0 0
Spain
State/province [103] 0 0
Salamanca
Country [104] 0 0
Spain
State/province [104] 0 0
Valencia
Country [105] 0 0
Sweden
State/province [105] 0 0
Lund
Country [106] 0 0
Sweden
State/province [106] 0 0
Stockholm
Country [107] 0 0
Sweden
State/province [107] 0 0
Uppsala
Country [108] 0 0
Switzerland
State/province [108] 0 0
Aarau
Country [109] 0 0
Switzerland
State/province [109] 0 0
St Gallen
Country [110] 0 0
Taiwan
State/province [110] 0 0
Kaohsiung
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taiching
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taipei
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Edinburgh
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Gillingham
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Glasgow
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Leeds
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Liverpool
Country [118] 0 0
United Kingdom
State/province [118] 0 0
London
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Newcastle
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Norwich
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Nottingham
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Ariad Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
Trial website
https://clinicaltrials.gov/study/NCT01650805
Trial related presentations / publications
Hanley MJ, Diderichsen PM, Narasimhan N, Srivastava S, Gupta N, Venkatakrishnan K. Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development. J Clin Pharmacol. 2022 Apr;62(4):555-567. doi: 10.1002/jcph.1990. Epub 2021 Dec 16.
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01650805